Protocol # 106-04: A Randomized, Phase III Multicenter, Controlled Trial to Evaluate the Efficacy and Safety of IDEC-Y2B8 Radioimmunotherapy Compared to Rituxan Immunotherapy of Relapsed or Refractory Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma

Project: Research project

Project Details

StatusFinished
Effective start/end date2/16/981/1/11

Funding

  • IDEC Pharmaceuticals Corporation (Protocol # 106-04)